LIGAND PHARMACEUTICALS INC Quarterly Income Tax Expense (Benefit) in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Ligand Pharmaceuticals Inc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2010 to Q3 2024.
  • Ligand Pharmaceuticals Inc Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $833K.
  • Ligand Pharmaceuticals Inc Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $13.6M, a 72.6% decline year-over-year.
  • Ligand Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2023 was $9.84M, a 76.1% decline from 2022.
  • Ligand Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2022 was $41.2M.
  • Ligand Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2021 was -$4.15M, a 21.8% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $13.6M $833K +$2.7M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $10.9M -$13.5M -$14.4M -1630% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $25.2M $27.3M +$15.4M +129% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $9.84M -$1.09M -$39.8M -103% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $49.6M -$1.87M -$4.58M -169% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 $54.2M $881K +$4.82M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $49.4M $11.9M +$8.14M +215% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $41.2M $38.7M +$34.6M +847% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $6.64M $2.71M +$1.17M +76.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $5.47M -$3.94M -$6.51M -253% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $12M $3.79M +$16.1M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$4.15M $4.08M +$6.47M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$10.6M $1.54M +$6.45M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$17.1M $2.58M -$3.46M -57.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$13.6M -$12.3M -$6.06M -96.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$7.55M -$2.39M -$1.58M -195% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-24
Q3 2020 -$5.97M -$4.91M -$291K -6.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$5.68M $6.03M +$9.64M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$15.3M -$6.28M -$183M -104% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $167M -$810K +$13.5M +94.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-24
Q3 2019 $154M -$4.62M -$16.5M -139% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-24
Q2 2019 $170M -$3.61M -$26M -116% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-24
Q1 2019 $196M $176M +$166M +1658% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-24
Q4 2018 $30M -$14.3M $0 0% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 $30M $11.9M $0 0% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 $30M $22.4M $0 0% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 $30M $10M $0 0% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 $30M -$14.3M -$24.7M -238% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 $54.7M $11.9M +$11.7M +7315% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 $43M $22.4M +$26.3M Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 $16.7M $10M +$6.34M +172% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 $10.3M $10.4M +$10.9M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$541K $160K +$192M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 -$193M -$3.88M -$4.15M -1565% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 -$188M $3.69M +$3.68M +24527% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 -$192M -$514K -$794K -284% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-28
Q3 2015 -$191M -$192M -$192M -154843% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-28
Q2 2015 $684K $265K +$312K Apr 1, 2015 Jun 30, 2015 10-K 2017-02-28
Q1 2015 $372K $15K -$38K -71.7% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-28
Q4 2014 $410K $280K +$142K +103% Oct 1, 2014 Dec 31, 2014 10-K/A 2016-11-15
Q3 2014 $268K $124K +$64K +107% Jul 1, 2014 Sep 30, 2014 10-K/A 2016-11-15
Q2 2014 $204K -$47K -$157K -143% Apr 1, 2014 Jun 30, 2014 10-K/A 2016-11-15
Q1 2014 $361K $53K -$13K -19.7% Jan 1, 2014 Mar 31, 2014 10-K/A 2016-11-15
Q4 2013 $374K $138K +$1.77M Oct 1, 2013 Dec 31, 2013 10-K 2015-02-23
Q3 2013 -$1.4M $60K -$82K -57.7% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-23
Q2 2013 -$1.32M $110K -$228K -67.5% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-23
Q1 2013 -$1.09M $66K +$101K Jan 1, 2013 Mar 31, 2013 10-K 2015-02-23
Q4 2012 -$1.19M -$1.64M Oct 1, 2012 Dec 31, 2012 10-K/A 2014-12-12
Q3 2012 $142K +$120K +545% Jul 1, 2012 Sep 30, 2012 10-K/A 2014-12-12
Q2 2012 $338K +$197K +140% Apr 1, 2012 Jun 30, 2012 10-K/A 2014-12-12
Q1 2012 -$35K Jan 1, 2012 Mar 31, 2012 10-K/A 2014-12-12
Q3 2011 $22K -$397K -94.7% Jul 1, 2011 Sep 30, 2011 10-Q/A 2012-02-10
Q2 2011 $141K -$484K -77.4% Apr 1, 2011 Jun 30, 2011 10-Q/A 2012-02-10
Q3 2010 $419K Jul 1, 2010 Sep 30, 2010 10-Q/A 2012-02-10
Q2 2010 $625K Apr 1, 2010 Jun 30, 2010 10-Q/A 2012-02-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.